Searched for
BIOCON FINANCIAL RESULTS
From Adani Green to Tata Tech: 50 companies swing back to profit in Q4 despite market turmoilIndian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Stocks in news: BSE, Britannia, Paytm, Meesho, RILIndian markets showed resilience, climbing despite volatility, buoyed by positive global trends and falling crude oil prices. Analysts anti...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Biocon shares in focus as Q4 PAT soars 153% YoYBiocon shares: The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on-year increase on a like-for-like ...
- Biocon Q4 results: Net profit surges 153% at Rs 344 croreBiocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's bi...
- Biocon shares fall 6% after Q2 net profit dives 84%. What should investors do?Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...
- Biocon Q4 Results: Net profit slumps 57% YoY to Rs 135 croreBiocon Q4 Results: Revenue from operations increased 16% year-on-year (YoY) to Rs 2,947 crore in the January-March 2024 period.
- Stocks in news: Biocon, Nykaa, Britannia, Tata Consumer, NestleBiocon has tentative approval from USFDA for Dasatinib Tablets, which are used to treat Philadelphia Chromosome Positive Chronic Myeloid Le...
- Malaysian facility to be commercialised in H2 FY17: BioconInitially, the products from the facility will cater to local markets but they would be taken gradually to global markets, Kiran Mazumdar-S...
- Syngene listing sparks Kiran Mazumdar-Shaw’s R&D dreamsFor Biocon Chairperson Kiran Mazumdar-Shaw, the listing of Syngene is a peaking point, bringing to fruition an effort that started 5 years ...
- R&D will continue to dive Biocon run: Gaurang ShahR&D could put pressure on the cash flows at least in the short to medium term but over a longer period of time we do remain positive on Bio...
- GE capital picks up 7.69% in Biocon's Syngene for Rs 125 croreThe total valuation of Syngene with this investment stands at Rs 1600 cr. Following the news, Biocon shares jumped by over 3%.
Load More
